Skip to main content

Advertisement

SpringerLink
Log in

Effects of Cholinesterase Inhibitors on Behavioural Disturbances in Alzheimer’s Disease

A Systematic Review

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Behavioural disturbances, also termed neuropsychiatric symptoms, are a frequent clinical feature of dementia in Alzheimer’s disease (AD). Many AD patients receive treatment with cholinesterase inhibitors (ChEIs). This review examines the evidence for behavioural effects of the four ChEIs that have been approved for the treatment of mild to moderate AD.

A systematic search of the MEDLINE and EMBASE databases and the Cochrane Library was conducted to identify clinical trials that had a randomised, placebo-controlled design. Studies were included in this review if they enrolled patients who had received a diagnosis of probable AD, involved at least one ChEI, and used an appropriate instrument for the assessment of behavioural disturbances.

Fourteen studies that matched the selection criteria were identified in the literature. A statistically significant difference between active treatment and placebo with regard to behavioural symptoms was observed in three of the 14 studies. Treatment effects varied between 2.0 and 6.2 points on the Neuropsychiatric Inventory.

ChEIs have moderate effects when used as a blanket treatment for the cluster of behavioural disturbances in AD. With regard to the limitations of the available trials, and in view of the risks that are associated with the use of atypical antipsychotics, the potential of ChEIs for the management of specific neuropsychiatric symptoms in patients with AD should be explored in further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997; 54: 257–63

    Article  PubMed  CAS  Google Scholar 

  2. Holtzer R, Tang MX, Devanand DP, et al. Psychopathological features in Alzheimer’s disease: course and relationship with cognitive status. J Am Geriatr Soc 2003; 51: 953–9

    Article  PubMed  Google Scholar 

  3. Hart DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer’s disease. Int J Geriat Psychiatry 2003; 18: 1037–42

    Article  CAS  Google Scholar 

  4. Coen RF, Swanwick GRJ, O’Boyle CA, et al. Behaviour disturbance and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12: 331–6

    Article  PubMed  CAS  Google Scholar 

  5. Hope T, Keene J, Gedling K, et al. Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriat Psychiatry 1998; 13: 682–90

    Article  CAS  Google Scholar 

  6. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990; 147: 1049–51

    PubMed  CAS  Google Scholar 

  7. Covinsky KE, Newcomer R, Fox P, et al. Patient and caregiver characteristics associated with depression in caregivers of patients with dementia. J Gen Intern Med 2003; 18: 1058–9

    Article  Google Scholar 

  8. Giron MS, Forsell Y, Bernsten C, et al. Psychotropic drug use in elderly people with and without dementia. Int J Geriat Psychiatry 2001; 16: 900–6

    Article  CAS  Google Scholar 

  9. Wilhelm-Goessling C. Antipsychotics given to elderly demented patients. Course in nursing homes after psychiatric hospital treatment. Nervenarzt 1998; 69: 999–1006

    Article  Google Scholar 

  10. Lanctot KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550–61

    Article  PubMed  CAS  Google Scholar 

  11. Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002; 19: 257–76

    Article  PubMed  CAS  Google Scholar 

  12. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43

    Article  PubMed  CAS  Google Scholar 

  13. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006: CD003476

    Google Scholar 

  14. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003; 51: 1305–17

    Article  PubMed  Google Scholar 

  15. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–15

    Article  PubMed  CAS  Google Scholar 

  16. McKhann G, Folstein M, Katzman R, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44

    Article  PubMed  CAS  Google Scholar 

  17. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrafydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. N Engl J Med 1990; 322: 1272–6

    Article  PubMed  CAS  Google Scholar 

  18. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. New Engl J Med 1992; 327: 1253–9

    Article  PubMed  CAS  Google Scholar 

  19. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9

    Article  PubMed  CAS  Google Scholar 

  20. Forette F, Hoover T, Gracon S, et al. A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer’s disease. Eur J Neurol 1995; 2: 229–38

    Article  Google Scholar 

  21. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91

    Article  PubMed  CAS  Google Scholar 

  22. Wood PC, Castleden CM. A double-blind, placebo controlled, multicentre study of tacrine for Alzheimer’s disease. Int J Geriatr Psychiatry 1994; 9: 649–54

    Article  Google Scholar 

  23. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20

    Article  PubMed  CAS  Google Scholar 

  24. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214–9

    Article  PubMed  CAS  Google Scholar 

  25. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheiemer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–9

    Article  PubMed  CAS  Google Scholar 

  26. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-conrolled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–95

    Article  PubMed  CAS  Google Scholar 

  27. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry 2004; 161: 532–8

    Article  PubMed  Google Scholar 

  28. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–95

    Article  PubMed  CAS  Google Scholar 

  29. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852–6

    Article  PubMed  Google Scholar 

  30. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14

    Article  PubMed  CAS  Google Scholar 

  31. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64

    PubMed  CAS  Google Scholar 

  32. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134–9

    PubMed  CAS  Google Scholar 

  33. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48: 9–15

    PubMed  Google Scholar 

  34. Folstein MF, Folstein SE, McHugh PR. ‘Mini Mental State’. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189–98

    Article  PubMed  CAS  Google Scholar 

  35. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer’s disease. Neurology 2000; 54: 2269–76

    Article  PubMed  CAS  Google Scholar 

  36. Dubois B, McKeith I, Orgogozo JM, et al. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer’s disease: the MALT study. Int J Geriatr Psychiatry 1999; 14: 973–82

    Article  PubMed  CAS  Google Scholar 

  37. Lopez-Arrieta JM, Schneider L. Metrifonate for Alzheimer’s disease. Cochrane Database Syst Rev 2006: CD003155

    Google Scholar 

  38. Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev 2006; 127: 158–65

    Article  PubMed  CAS  Google Scholar 

  39. Trinh N, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003; 289: 210–6

    Article  PubMed  CAS  Google Scholar 

  40. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722–30

    PubMed  Google Scholar 

  41. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005; 293: 596–608

    Article  PubMed  CAS  Google Scholar 

  42. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 463–7

    Article  PubMed  Google Scholar 

  43. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19: 115–26

    Article  PubMed  Google Scholar 

  44. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ 2005; 330(7496): 874

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Technische Universität München, Moehlstrasse 26, Munich, 81675, Germany

    Timo Grimmer & Alexander Kurz

Authors
  1. Timo Grimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Kurz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timo Grimmer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grimmer, T., Kurz, A. Effects of Cholinesterase Inhibitors on Behavioural Disturbances in Alzheimer’s Disease. Drugs Aging 23, 957–967 (2006). https://doi.org/10.2165/00002512-200623120-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200623120-00003

Keywords

Search

Navigation